About this trial
Patients at high risk of post-operative pulmonary complications (PPC) will be screened out from gynecological tumor patients undergoing surgical treatment, and randomly assigned into the HFNC group and control group, which uses conventional nasal cannula oxygen therapy. The primary outcome is the incidence of PPC, including postoperative hypoxemia, atelectasis, pneumonia, etc. Secondary outcomes are the improvement of postoperative oxygenation, antibiotic use, length of hospital stay, adverse events related to oxygen therapy, etc.
Eligibility criteria
Qualifiers
Assess respiratory risk in surgical patients in Catalonia (ARRSPC) ≥45 points;
BMI≥30;
Moderate to severe asthma;
Moderate to severe chronic obstructive pulmonary disease (COPD);
Disqualifiers
Patients with lung metastasis of malignant tumor or primary lung malignant tumor;
previous lung surgery or radiotherapy;
the surgery involved segmental bowel resection.
Trial design
Treatments tested in this trial
- heated humidified high flow nasal cannula oxygen therapy, HFNC
- Nasal cannula oxygen